BI
AKRO

BVF Inc’s Akero Therapeutics AKRO Stock Holding History

BVF Inc’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-282,862
Closed -$6M – 58
2020
Q1 		$6M Sell
282,862
-168,147
-37% -$3.61M 0.56% 35
2019
Q4 		$10M Sell
451,009
-20,737
-4% -$429K 0.76% 32
2019
Q3 		$10.7M Sell
471,746
-176,602
-27% -$4.11M 1.13% 27
2019
Q2 		$12.4M Buy
+648,348
New +$12.3M 1.36% 25

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc's AKRO Position: Q2 2020 in Review

BVF Inc sold out of Akero Therapeutics (AKRO) in Q2 2020, closing a stake of 282,862 shares — an estimated $6M sold.

BVF Inc first reported a position in AKRO in Q2 2019 and held it in 4 quarters. The position peaked at $12.4M in Q2 2019. 79 funds tracked by Wall St. Rank hold AKRO as of Q2 2020.

  • BVF Inc reported no remaining Akero Therapeutics position as of Q2 2020 after selling out during the quarter.
  • BVF Inc sold 282,862 Akero Therapeutics shares in Q2 2020, an estimated $6M.
  • BVF Inc first reported a position in Akero Therapeutics in Q2 2019 and held it in 4 quarters.
  • BVF Inc's Akero Therapeutics position peaked at $12.4M in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2020.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.